Previous 10 | Next 10 |
Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel PR Newswire - New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SA...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Invitae (NYSE: NVTA ) have had a disastrous 2022 so far. Today, the genetic information company is down more than 10%, bringing its year-to-date decline to more than 60%. Source: Connect world / Shutterst...
The following slide deck was published by Invitae Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Invitae Corporation 2022 Q1 - Results - Earnings Call Presentation
Shares of Invitae (NYSE: NVTA) were tumbling 9.6% lower as of 10:24 a.m. ET on Wednesday. The decline came after the medical genetics company announced its first-quarter results following the market close on Tuesday. Invitae reported first-quarter revenue of $123.7 million, up 1...
Image source: The Motley Fool. Invitae (NYSE: NVTA) Q1 2022 Earnings Call May 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Invitae (NVTA) Q1 2022 Earnings Call Transcript
Invitae Corporation (NVTA) Q1 2022 Results Conference Call May 03, 2022 04:30 PM ET Company Participants Jack Finks - IR Sean George - CEO Roxi Wen - CFO Conference Call Participants Daniel Brennan - Cowen Tejas Savant - Morgan Stanley Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs ...
Invitae (NYSE:NVTA) saw its Q1 2022 net loss widen 66% to $181.9M as the genetic test maker was hampered in the quarter by increases in R&D, and sales and marketing costs. Both the net loss and revenue of $123.7M -- though a ~19% year-over-year increase -- both missed consensus estimates....
Invitae press release (NYSE:NVTA): Q1 Non-GAAP EPS of -$0.78 misses by $0.02. Revenue of $123.69M (+19.4% Y/Y) misses by $5.62M. At March 31, 2022, cash, cash equivalents, restricted cash and marketable securities totaled $885 million as compared with $1.06 billion as of December 31...
Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway PR Newswire — Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash* , an annualized burn reduction of greater than $1...
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer PR Newswire Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the lif...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...